Expression of B cell-specific activator protein/PAX5 in acute myeloid leukemia with t(8;21)(q22;q22)

The blasts of acute myeloid leukemia (AML) with t(8;21)(q22;q22) frequently express the B-cell antigen CD19, which is regulated by B cell-specific activator protein (BSAP) encoded by the PAX5 gene, a protein important for B-cell lineage commitment and development. We assessed for BSAP expression in...

Full description

Saved in:
Bibliographic Details
Published in:American journal of clinical pathology 2006-08, Vol.126 (2), p.235-240
Main Authors: VALBUENA, Jose R, MEDEIROS, L. Jeffrey, RASSIDAKIS, George Z, SUYANG HAO, WU, C. Daniel, LEI CHEN, PEI LIN
Format: Article
Language:English
Subjects:
Acute Disease
Biological and medical sciences
Biomarkers, Tumor - metabolism
Chromosome Banding
Chromosomes, Human, Pair 21 - genetics
Chromosomes, Human, Pair 8 - genetics
Flow Cytometry
Fluorescent Antibody Technique, Indirect
Hematologic and hematopoietic diseases
Humans
Immunoenzyme Techniques
Investigative techniques, diagnostic techniques (general aspects)
Leukemia, Myeloid - genetics
Leukemia, Myeloid - metabolism
Leukemia, Myeloid - pathology
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Medical sciences
Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques
PAX5 Transcription Factor - genetics
PAX5 Transcription Factor - metabolism
Translocation, Genetic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The blasts of acute myeloid leukemia (AML) with t(8;21)(q22;q22) frequently express the B-cell antigen CD19, which is regulated by B cell-specific activator protein (BSAP) encoded by the PAX5 gene, a protein important for B-cell lineage commitment and development. We assessed for BSAP expression in 28 AML cases with t(8;21) and 46 AML cases of other types. CD19 was expressed by 26 (93%) cases of AML with t(8;21) and 1 AML case (2%) without t(8;21). We also tested a subset of cases for the B-cell transcription factors Oct2 and OCA-B (BOB.1) and the B-cell antigens CD20, CD22, and CD79a. Immunostaining performed on bone marrow biopsy specimens demonstrated BSAP expression in all 28 AML cases with t(8;21): weak, 21; strong, 7. By contrast, BSAP was expressed weakly in only 1 AML case without t(8;21). Oct2 was expressed strongly in 12 of 16 AML cases with t(8;21) and 19 of 46 without t(8;21). OCA-B, CD20, CD22, or CD79a were negative in all cases assessed. These results indicate that silencing of PAX5 is not required for commitment to myeloid differentiation and that BSAP expression in AML is found mainly in cases with t(8;21).
ISSN:0002-9173
1943-7722
DOI:10.1309/LG0Q0VXYBETJ4VHE